Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer ; day:6 ; month:7 ; year:2023 ; pages:1-7
Irish journal of medical science ; (6.7.2023), 1-7
- Creator
-
Zou, Bing-Zi
Wen, Hong
Luo, Huan-Jia
Luo, Wan-Chao
Xie, Qi-Tong
Zhou, Meng-Ting
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11845-023-03448-w
- URN
-
urn:nbn:de:101:1-2023100508575322418397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zou, Bing-Zi
- Wen, Hong
- Luo, Huan-Jia
- Luo, Wan-Chao
- Xie, Qi-Tong
- Zhou, Meng-Ting
- SpringerLink (Online service)
Other Objects (12)
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen testing patterns and prostate cancer stage at diagnosis in older Ohio cancer patients
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen testing patterns and prostate cancer stage at diagnosis in older Ohio cancer patients
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen testing patterns and prostate cancer stage at diagnosis in older Ohio cancer patients
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen